509 related articles for article (PubMed ID: 18952572)
21. Inside epoxyeicosatrienoic acids and cardiovascular disease.
Tacconelli S; Patrignani P
Front Pharmacol; 2014; 5():239. PubMed ID: 25426071
[TBL] [Abstract][Full Text] [Related]
22. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism.
Marowsky A; Burgener J; Falck JR; Fritschy JM; Arand M
Neuroscience; 2009 Oct; 163(2):646-61. PubMed ID: 19540314
[TBL] [Abstract][Full Text] [Related]
23. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.
Sacerdoti D; Gatta A; McGiff JC
Prostaglandins Other Lipid Mediat; 2003 Oct; 72(1-2):51-71. PubMed ID: 14626496
[TBL] [Abstract][Full Text] [Related]
24. Regulation of forskolin-induced cAMP production by cytochrome P450 epoxygenase metabolites of arachidonic acid in HEK293 cells.
Abukhashim M; Wiebe GJ; Seubert JM
Cell Biol Toxicol; 2011 Oct; 27(5):321-32. PubMed ID: 21519968
[TBL] [Abstract][Full Text] [Related]
25. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease.
Schuck RN; Zha W; Edin ML; Gruzdev A; Vendrov KC; Miller TM; Xu Z; Lih FB; DeGraff LM; Tomer KB; Jones HM; Makowski L; Huang L; Poloyac SM; Zeldin DC; Lee CR
PLoS One; 2014; 9(10):e110162. PubMed ID: 25310404
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.
Spector AA; Kim HY
Biochim Biophys Acta; 2015 Apr; 1851(4):356-65. PubMed ID: 25093613
[TBL] [Abstract][Full Text] [Related]
27. Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury.
Nithipatikom K; Moore JM; Isbell MA; Falck JR; Gross GJ
Am J Physiol Heart Circ Physiol; 2006 Aug; 291(2):H537-42. PubMed ID: 16473964
[TBL] [Abstract][Full Text] [Related]
28. Increases in levels of epoxyeicosatrienoic and dihydroxyeicosatrienoic acids (EETs and DHETs) in liver and heart in vivo by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and in hepatic EET:DHET ratios by cotreatment with TCDD and the soluble epoxide hydrolase inhibitor AUDA.
Diani-Moore S; Ma Y; Gross SS; Rifkind AB
Drug Metab Dispos; 2014 Feb; 42(2):294-300. PubMed ID: 24311719
[TBL] [Abstract][Full Text] [Related]
29. Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels.
Iliff JJ; Wang R; Zeldin DC; Alkayed NJ
Am J Physiol Heart Circ Physiol; 2009 May; 296(5):H1352-63. PubMed ID: 19304946
[TBL] [Abstract][Full Text] [Related]
30. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
31. Role of Cytochrome p450 and Soluble Epoxide Hydrolase Enzymes and Their Associated Metabolites in the Pathogenesis of Diabetic Cardiomyopathy.
Maayah ZH; McGinn E; Al Batran R; Gopal K; Ussher JR; El-Kadi AOS
J Cardiovasc Pharmacol; 2019 Sep; 74(3):235-245. PubMed ID: 31306370
[TBL] [Abstract][Full Text] [Related]
32. Vascular pharmacology of epoxyeicosatrienoic acids.
Pfister SL; Gauthier KM; Campbell WB
Adv Pharmacol; 2010; 60():27-59. PubMed ID: 21081214
[TBL] [Abstract][Full Text] [Related]
33. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation.
Oltman CL; Weintraub NL; VanRollins M; Dellsperger KC
Circ Res; 1998 Nov; 83(9):932-9. PubMed ID: 9797342
[TBL] [Abstract][Full Text] [Related]
34. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
[TBL] [Abstract][Full Text] [Related]
35. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P
J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337
[TBL] [Abstract][Full Text] [Related]
36. Differential effect of amyloid β on the cytochrome P450 epoxygenase activity in rat brain.
Sarkar P; Narayanan J; Harder DR
Neuroscience; 2011 Oct; 194():241-9. PubMed ID: 21843605
[TBL] [Abstract][Full Text] [Related]
37. Role of epoxyeicosatrienoic acids in cardiovascular diseases and cardiotoxicity of drugs.
Zhang Y; Gao L; Yao B; Huang S; Zhang Y; Liu J; Liu Z; Wang X
Life Sci; 2022 Dec; 310():121122. PubMed ID: 36309225
[TBL] [Abstract][Full Text] [Related]
38. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
[TBL] [Abstract][Full Text] [Related]
39. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
[TBL] [Abstract][Full Text] [Related]
40. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha.
Fang X; Hu S; Xu B; Snyder GD; Harmon S; Yao J; Liu Y; Sangras B; Falck JR; Weintraub NL; Spector AA
Am J Physiol Heart Circ Physiol; 2006 Jan; 290(1):H55-63. PubMed ID: 16113065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
